Chemocentryx (CCXI) Awarded $500K FDA Grant
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Chemocentryx, Inc. (NASDAQ: CCXI) receives a $500,000 annual grant from the FDA: Petrus Bekker, Phase 2 Study of CCX168 for the Treatment of Anti-Neutrophil Cytoplasmic Auto-Antibodies Associated Vasculitis.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Dr Pepper Snapple Group (DPS) Said in Talks to Buy Bai Brands - Reuters
- Sarepta's (SRPT) Exondys 51 covered by Humana (HUM) with prior authorization - Bloomberg
- Minerva Neurosciences (NERV) Reports Six-Month Data from Phase IIb Trial of MIN-10 in Schizophrenia
Create E-mail Alert Related CategoriesCorporate News, FDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!